|
|
|
Insider
Information: |
Mehra Anand |
Relationship: |
Director |
City: |
Menlo Park |
State: |
CA |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
11 |
|
Direct
Shares |
11,769,795 |
|
Indirect Shares
|
6,925,513 |
|
|
Direct
Value |
$208,767,505 |
|
|
Indirect Value
|
$114,026,792 |
|
|
Total
Shares |
18,695,308 |
|
|
Total
Value |
$322,794,297 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
0
|
0
|
Stock
price went up :
|
0
|
0
|
Stock
price went down : |
0
|
0
|
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
Percentage
Gain/Loss : |
0.0%
|
0.0%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Aerie Pharmaceuticals Inc |
AERI |
Director |
2015-04-10 |
1,700 |
2015-04-15 |
469,591 |
Premium* |
|
Alimera Sciences Inc |
ALIM |
10% Owner |
2014-09-12 |
40,020 |
2014-09-12 |
506,270 |
Premium* |
|
Ocugen Ord Shs |
OCGN |
10% Owner |
2014-12-08 |
0 |
2014-12-08 |
2,077,040 |
Premium* |
|
Spark Therapeutics, Inc. |
ONCE |
Director |
2019-12-17 |
0 |
2019-12-17 |
0 |
Premium* |
|
aTyr Pharma Inc |
LIFE |
10% Owner |
2015-05-12 |
1,866,126 |
2015-05-12 |
0 |
Premium* |
|
Synlogic Inc |
SYBX |
10% Owner |
2015-10-06 |
2,974,811 |
2015-10-05 |
0 |
Premium* |
|
Aclaris Therapeutics, Inc. |
ACRS |
Director |
2023-06-02 |
38,704 |
2018-10-22 |
1,911,573 |
Premium* |
|
Iterum Therapeutics Plc |
ITRM |
10% Owner |
2018-05-30 |
1,726,514 |
2018-05-30 |
0 |
Premium* |
|
Principia Biopharma Inc |
PRNB |
10% Owner |
2018-09-18 |
2,038,208 |
2018-09-18 |
0 |
Premium* |
|
Galera Therapeutics, Inc. |
GRTX |
10% Owner |
2019-11-12 |
3,083,712 |
2019-11-12 |
0 |
Premium* |
|
Merus Nv |
MRUS |
Director |
|
0 |
2020-01-01 |
1,961,039 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
78 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 3 of 4
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
ONCE |
Spark Therapeutics, Inc. |
Director |
|
2017-02-15 |
4 |
AS |
$65.03 |
$2,048,250 |
I/I |
(31,497) |
809,794 |
0 |
- |
|
ONCE |
Spark Therapeutics, Inc. |
Director |
|
2017-02-16 |
4 |
AS |
$65.01 |
$188,529 |
I/I |
(2,900) |
806,894 |
0 |
- |
|
ONCE |
Spark Therapeutics, Inc. |
Director |
|
2017-02-17 |
4 |
AS |
$65.01 |
$489,850 |
I/I |
(7,535) |
799,359 |
0 |
- |
|
ONCE |
Spark Therapeutics, Inc. |
Director |
|
2017-02-27 |
4 |
AS |
$65.02 |
$2,724,988 |
I/I |
(41,910) |
757,449 |
0 |
- |
|
ONCE |
Spark Therapeutics, Inc. |
Director |
|
2017-02-28 |
4 |
AS |
$65.02 |
$1,643,315 |
I/I |
(25,274) |
732,175 |
0 |
- |
|
ONCE |
Spark Therapeutics, Inc. |
Director |
|
2017-03-01 |
4 |
AS |
$65.01 |
$1,135,725 |
I/I |
(17,470) |
714,705 |
0 |
- |
|
ONCE |
Spark Therapeutics, Inc. |
Director |
|
2017-03-02 |
4 |
AS |
$65.01 |
$993,028 |
I/I |
(15,275) |
699,430 |
0 |
- |
|
ONCE |
Spark Therapeutics, Inc. |
Director |
|
2017-06-20 |
4 |
AS |
$65.00 |
$66,300 |
I/I |
(1,020) |
698,410 |
0 |
- |
|
ONCE |
Spark Therapeutics, Inc. |
Director |
|
2017-06-21 |
4 |
AS |
$65.00 |
$343,330 |
I/I |
(5,282) |
693,128 |
0 |
- |
|
ONCE |
Spark Therapeutics, Inc. |
Director |
|
2017-07-24 |
4 |
AS |
$70.04 |
$14,861,993 |
I/I |
(211,858) |
481,270 |
0 |
- |
|
ITRM |
Iterum Therapeutics Plc |
10% Owner |
|
2018-05-30 |
4 |
A |
$0.00 |
$0 |
D/D |
1,226,514 |
1,226,514 |
0 |
- |
|
ITRM |
Iterum Therapeutics Plc |
10% Owner |
|
2018-05-30 |
4 |
B |
$13.00 |
$6,500,000 |
D/D |
500,000 |
1,726,514 |
2.45 |
- |
|
ONCE |
Spark Therapeutics, Inc. |
Director |
|
2018-05-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,500 |
1,500 |
0 |
- |
|
PRNB |
Principia Biopharma Inc |
10% Owner |
|
2018-09-18 |
4 |
A |
$0.00 |
$0 |
D/D |
1,768,208 |
1,768,208 |
0 |
- |
|
PRNB |
Principia Biopharma Inc |
10% Owner |
|
2018-09-18 |
4 |
B |
$17.00 |
$4,590,000 |
D/D |
270,000 |
2,038,208 |
2.45 |
- |
|
ACRS |
Aclaris Therapeutics, Inc... |
Director |
|
2018-10-22 |
4 |
B |
$10.75 |
$4,000,000 |
I/I |
372,093 |
1,911,573 |
2.1 |
- |
|
ONCE |
Spark Therapeutics, Inc. |
Director |
|
2019-01-04 |
4 |
OE |
$3.45 |
$128,350 |
D/D |
37,203 |
38,703 |
0 |
- |
|
ONCE |
Spark Therapeutics, Inc. |
Director |
|
2019-05-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,500 |
40,203 |
0 |
- |
|
GRTX |
Galera Therapeutics, Inc. |
10% Owner |
|
2019-11-12 |
4 |
B |
$12.00 |
$9,000,000 |
D/D |
750,000 |
3,083,712 |
2.45 |
- |
|
GRTX |
Galera Therapeutics, Inc. |
10% Owner |
|
2019-11-12 |
4 |
A |
$0.00 |
$0 |
D/D |
2,333,712 |
2,333,712 |
0 |
- |
|
ONCE |
Spark Therapeutics, Inc. |
Director |
|
2019-12-17 |
4 |
D |
$114.50 |
$4,603,244 |
D/D |
(40,203) |
0 |
0 |
- |
|
ONCE |
Spark Therapeutics, Inc. |
Director |
|
2019-12-17 |
4 |
D |
$114.50 |
$55,105,415 |
I/I |
(481,270) |
0 |
0 |
- |
|
ACRS |
Aclaris Therapeutics, Inc... |
Director |
|
2020-03-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,876 |
8,876 |
0 |
- |
|
ACRS |
Aclaris Therapeutics, Inc... |
Director |
|
2020-06-06 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,333 |
16,209 |
0 |
- |
|
ACRS |
Aclaris Therapeutics, Inc... |
Director |
|
2021-02-02 |
4 |
OE |
$18.32 |
$268,298 |
D/D |
14,632 |
30,841 |
0 |
- |
|
78 Records found
|
|
Page 3 of 4 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|